title: Evaluation of postoperative antibiotic prophylaxis after liver resection: a randomized controlled trial.
abstract: BACKGROUND
  Antibiotic prophylaxis is frequently administered after liver resection to prevent postoperative infections. However, very few studies have examined the usefulness of antibiotic prophylaxis after liver resection. A randomized controlled trial was conducted to evaluate the postoperative antibiotic prophylaxis in patients after liver resection.
  
  
  METHODS
  A total of 241 patients scheduled to undergo liver resection were randomly assigned to the non-postoperative antibiotic group (n = 95) or the antibiotic group (n = 95). The antibiotic group was given flomoxef sodium every 12 hours for 3 days after the operation. The end point was signs of infection, surgical site infection, or infectious complications.
  
  
  RESULTS
  There were no significant differences between the 2 groups in signs of infection (21.3% vs 25.5%, P = .606), the incidence of systemic inflammatory response syndrome (11.7% vs 17.0%, P = .406), infectious complications (7.5% vs 17.0%, P = .073), surgical site infection (10.6% vs 13.8%, P = .657), and remote site infection (2.1% vs 8.5%, P = .100).
  
  
  CONCLUSIONS
  Postoperative antibiotic prophylaxis cannot prevent postoperative infections after liver resection, and it is thought that antibiotic prophylaxis is unnecessary and costly.
authors.affiliation: Department of General and Gastroenterological Surgery, Osaka Medical College, Osaka, Japan. sur122@poh.osaka-med.ac.jp
authors.forename: Fumitoshi
authors.initials: F
authors.lastname: Hirokawa
authors.forename: Michihiro
authors.initials: M
authors.lastname: Hayashi
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Miyamoto
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Asakuma
authors.forename: Tetsunosuke
authors.initials: T
authors.lastname: Shimizu
authors.forename: Koji
authors.initials: K
authors.lastname: Komeda
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Inoue
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Uchiyama
authors.forename: Yasuichiro
authors.initials: Y
authors.lastname: Nishimura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis / Q000191:economics / Q000379:methods; D015415:Biomarkers / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000601:surgery; D002511:Cephalosporins / Q000627:therapeutic use*; D018281:Cholangiocarcinoma / Q000601:surgery; D005260:Female; D006498:Hepatectomy / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D007239:Infections / Q000209:etiology* / Q000382:microbiology; D008113:Liver Neoplasms / Q000378:metabolism / Q000556:secondary / Q000601:surgery*; D016031:Liver Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D013530:Surgical Wound Infection / Q000209:etiology / Q000382:microbiology / Q000517:prevention & control; D018746:Systemic Inflammatory Response Syndrome / Q000209:etiology / Q000517:prevention & control; D017211:Treatment Failure
chemical_list: D000900:Anti-Bacterial Agents; D015415:Biomarkers; D002511:Cephalosporins; C045693:flomoxef